INTRODUCTION

8
Crohn's disease and ulcerative colitis (UC) are chronic inflammatory bowel diseases (IBD) with a significant 3 9 increase in occurrence worldwide [1, 2] . As UC is limited to the large bowel, up to 25% of patients with 4 0 intractable or complicated UC may undergo total large bowel resection with reconstruction of intestinal 4 1 continuity by creation of a reservoir ("pouch") from the normal small bowel connected to the anus (total and Streptococcus) in the fecal microbiomes of Abx+ patients had at least one occurrence of a putative resistant 8 0 allele in either gyrA or parC (Table 1 , Fig. 3a, Supplementary Fig. 4a ). For some other genera, resistant alleles 8 1
were also observed in Abx-patients (Fig. 3b, Supplementary Fig. 4b ), indicating that some of these alleles 8 2
probably do not incur a strong fitness cost and that for these genera (Bifidobacterium, Lactobacillus, Dialister, 8 3 Veillonella, Bacteroides and Prevotella) background FQ-resistance exists. Genera in which we detected double antibiotics may have unpredictable effects as far as which drug-resistant species they may enrich for.
0
Being able to quantitatively infer putative resistance from metagenomic data enabled us to determine Supplementary Fig. 4 ). The median fraction of community FQ-resistance in Abx+ samples was 72%, compared 9 3 to 9.4% in samples obtained in , Fig. 3d , Supplementary Table 5) .
4
Furthermore, in Abx+ microbiomes the mean abundance of resistant Enterobacterales and Lactobacillales was 9 5
24.4% and 35.7%, respectively, in contrast to only 1.13% and 0.6% in Abx-microbiomes (Mann-Whitney,
P=1.5x10 -5 for Enterobacterales, P=8.4x10 -6 for Lactobacillales, Fig. 3c , Supplementary Table 5) . Lastly, FQ-
sensitive Clostridiales had mean abundance of 52.8% in non-treated samples, but decreased to 10.8% during 9 8
C+M treatment, probably due to the strong effect of the combination of ciprofloxacin with metronidazole that is FQ-resistance may also be conferred by mobile resistance genes, and can be encoded on the mobile elements 0 5
that carry resistance genes to additional antibiotics. This may have clinical implications for the patients and 0 6
those that come in contact with them that are broader than resistance to the administered antibiotics. To obtain 0 7
an overall bacterial resistome in our samples, we profiled the assembled metagenomes for all antibiotic ciprofloxacin to topoisomerases, conferring moderate resistance to FQ and are usually plasmid encoded. We 2 0 detected qnrS1 in 25 samples from 18 patients and qnrB4 in 18 samples from 12 patients (Table 2) .
1
Surprisingly, these qnr genes were not significantly enriched in Abx+ samples. Similar to aac(6')-Ib-cr, the 2 2 contigs on which these qnr genes occurred matched sequences from known plasmids of E. coli and K. (Table 2) , and also encoded beta lactamases belonging to the TEM family [43] .
4
Healthy human gut microbiomes may contain antibiotic resistance genes even in untreated individuals 2 5 [21, 22] . Indeed, many such genes in our dataset were not treatment-associated. Beta-lactam, polymyxin, 2 6 macrolide, and tetracycline resistance genes, as well as efflux pump genes were commonly encountered in resistance genes were decreased in Abx+ samples, probably reflecting the decrease in species from Clostridiales 2 9
order that harbour these genes (Supplementary , Supplementary Fig. 6 ), which suggests that there is a general enrichment 3 9
of resistance genes in the microbiome following specific antibiotics treatment (of C+M). To infer how long 4 0 does antibiotic treatment-associated enrichment of resistance genes persist, we divided the samples based on the total reads mapped to assembled resistance genes in Abx+ compared to 0.55% in Abx-). In contrast, no 4 4 difference was observed in the fraction of resistance genes in samples that were antibiotic-free for 1-6 months 4 5 compared to those obtained when patients were free of antibiotics for over six months ( Supplementary Fig. 7b ).
6
Thus, most antibiotic resistance genes enrichment diminishes gradually in the months following treatment 4 7 discontinuation.
8
Taken together, our results suggest that although most FQ-resistance is chromosomal, chronic treatment
with a combination of C+M is associated with a higher risk of carriage of multidrug resistance plasmids and a inadvertently increase collateral resistance to non-related antibiotics for up to several months after antibiotics 5 2 discontinuation.
3
Bacterial density is moderately decreased following prolonged antibiotic treatment in patients with pouchitis
Antibiotics are the mainstay therapy for pouchitis, which is considered to be the most antibiotic-responsive
IBD. Yet the mechanisms underlying clinical response are unclear [6, 14, 45] . One possible explanation for the
clinical efficacy could be that by using broad spectrum antibiotics (e.g. C+M), the numbers of bacteria in the 5 7
pouch are greatly reduced, resulting in lower exposure to bacteria-derived antigens ("reducing antigenic load"),
thereby dampening inflammation. An alternative explanation is that there are specific bacterial taxa that greatly 5 9
contribute to inflammation ("pathobionts") and that these taxa are suppressed by antibiotics. To distinguish Table 2a ]. Since the levels of human and viral DNA in faeces should be relatively independent of those of
bacterial DNA, and shotgun metagenomics sequences all DNA irrespective of its origin, a higher fraction of 6 8 reads derived from bacteria should be strongly correlated with bacterial concentration in the sample. Human reads fraction ranged widely from 0.18% to 90.5%, with a mean of 8.3% and virus reads ranged from 0.07% to 7 0 27.7%, with a mean of 1.3% of the total reads in the metagenomes (Supplementary Table 2a ). To test the 7 1 agreement between qPCR measurements and our metagenome-inferred bacterial density, we plotted B/(H+V)
vs. qPCR-based bacterial density for 11 samples taken from patients with a pouch (Fig. 4a) . A strong linear 7 3 correlation (Pearson r=0.84, P=0.0012) between qPCR and B/(H+V) ratios was observed, indicating that our
metagenome-derived ratio well represents the bacterial density in fecal samples of patients with a pouch. We had lower bacterial density compared to patients with a normal pouch and FAP (Fig. 4d) . This may reflect their 8 4
antibiotic usage but also pouch inflammation, both of which can decrease the bacterial density in the pouch.
5
Previous work argued that antibiotic treatment failure in patients with pouchitis was due to these patients maintained clinical remission at time of treatment. Thus, the development of FQ-resistant bacteria 9 0
is not the major explanation for failure of antibiotic treatment. To expand on this, we surveyed our
metagenomes for Enterobacteriaceae-derived enterotoxin genes (SPATE -extracellular proteases secreted by
Enterobacteriaceae, see Methods, [49] ) and observed that only an average of 3.2% of the samples had putative metagenomes (Fisher exact test, P=1.3x10 -37 , Supplementary Table 7) . We also compared the prevalence of treatment. Therefore, antibiotic resistance of "usual suspects", such as Enterobacteriaceae, does not predict 9 8 treatment failure. this may seem surprising, the pervasive antibiotic-resistant alleles that we observed in those microbiomes can 0 7 explain these observations. We also showed collateral resistance, which can be attributed to co-localization of 0 8 different resistance genes on the same mobile element. This collateral resistance represents a concern for 0 9
patients and the community due to potential horizontal gene transfer of such elements to other bacteria or the 1 0 transmission of the resistant strains themselves.
1
Collectively, our data show that prolonged antibiotic treatment modestly reduces the bacterial density 1 2
and is unlikely to reduce the overall immune exposure to bacteria-derived antigens. This contradicts the 1 3 accepted assumption that the rationale for treating IBD, specifically pouchitis, with antibiotics is reduction of 1 4
antigenic load. We therefore suggest that suppression of pro-inflammatory pathobionts is a more likely Such treatments will improve upon the current standard of care that involves chronic treatment that inevitably 2 0 leads to collateral antibiotic resistance. 
MATERIALS AND METHODS
3
Study design and cohort details. Patients after pouch surgery were recruited at the Comprehensive Pouch Clinic where an IBD-oriented gastroenterologist and a colorectal surgeon routinely followed up all patients.
5
Pouch disease behaviour (phenotype) was defined as normal, acute/recurrent-acute, chronic or Crohn's-like undergoing pouch surgery due to familial adenomatous polyposis (FAP) were recruited as well. Briefly, a 2 8 normal pouch was defined as no pouchitis during the past 2 years and no antibiotic therapy. Acute/recurrent-2 9
acute pouchitis was defined as a flare of pouchitis responding to a short (usually 2 weeks) antibiotic therapy, or 3 0 up to 4 flares/year, respectively. Chronic pouchitis was defined as >4 pouchitis flares/year or the need for 3 1 chronic administration of antibiotic or IBD specific anti-inflammatory therapy for more than 1 month. CLDP was defined as having pouch-perianal disease, pouch strictures, or long segments of proximal small intestinal 3 3
inflammation.
4
Demographics and clinical data were collected during clinic visits. These included type of antibiotics Genomic libraries were prepared with the Nextera XT library preparation kit using approximately 1ng using Illumina NextSeq500 paired-end (2 x 150 bp reads) at DNA Services Facility, University of Illinois,
Chicago, IL, USA; 234 samples were obtained (after removal of low sequencing depth samples). The consisted of low-quality reads filtering and removal of low score bases and short reads. NCBI RefSeq or NR databases was used to assign taxonomic annotation to the genes. For each bacterial genus 1 7
gyr and par identified, we built a separate multiple sequence alignment of the amino-acid gyr/par sequences of 1 8
reference taxa downloaded from NCBI protein and compared it to gyr/par genes from our assemblies. The with isolated strains, a resistant allele; B -no support studies but appears in < 20% of the reference sequences parC, gyrB, parE), we found a high number of potential resistance variants only in gyrA and parC, which are 2 7 considered as the primary target genes for fluoroquinolones for most bacterial species. All the identified gyrA 2 8
and parC variants in our metagenome assemblies appear in Table 1 . Abundance information for gyrA / parC 2 9
was obtained using Bowtie2 as mentioned in the previous section. In addition, we wished to validate that in 3 0 cases where two mutations were detected in a specific gyrA sequence, it originated from a single strain. FQ-
sensitive E. coli gyrA nucleotide sequence was used as a reference and the metagenomic reads of each sample 3 2
were separately mapped against it with Bowtie2. Detection of variants between the reads and the reference 3 3
sequence (variant calling) was done using SAMtools mpileup in conjunction with BCFtools call v1.7-1 [66].
The double mutations in E. coli gyrA were found to cover single reads (in samples where E. coli was abundant 3 5 enough to do variant calling), confirming that the double mutant gyrA variant is a single strain. Bacterial density analysis through metagenomics. We have developed a method to measure relative bacterial used as reference and quantified as mentioned above. Both human and virus reads were filtered by mapping B/(H+V) ratios for each sample, we divided the number of bacterial reads by the sum of human and virus reads.
5
For the B(H+V) quantification of the metagenomes see Supplementary Table 2a . To model the effects of antibiotics and of clinical data on species richness in the microbiome, a (yes/no). All predictors were centered and scaled to account for the different variables scales using the function 7 0 scale in base R. Individual patient was specified as random effect. The model was implemented using glmer 7 1 function in R package lme4. Code availability. All the plots, statistical methods and custom scripts in this article were created using open- repository (https://cran.r-project.org). Table S1 . Study cohort demographics and samples metadata. Table S2 . Bacteria-Human-Virus ratios and metagenome assembly stats. Table S6 . Antibiotic resistance genes profiles. 
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